Stocktoria
Metagenomi Therapeutics, Inc. MGX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-02-09
Metagenomi Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating margin | -380.9% | -170.0% | -175.4% |
| Net margin | -348.5% | -149.3% | -152.5% |
| FCF margin | -354.9% | -214.5% | -226.2% |
| Return on assets | -39.7% | -24.0% | -18.7% |
| Return on equity | -55.4% | -33.2% | 50.3% |
| Current ratio | 7.22 | 6.91 | 4.04 |
| Revenue growth | -51.8% | 16.8% | — |
Source: SEC EDGAR filings · CIK 0001785279 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.